INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY WORLD HEALTH ORGANIZATION TOXICOLOGICAL EVALUATION OF SOME FOOD COLOURS, EMULSIFIERS, STABILIZERS, ANTI-CAKING AGENTS AND CERTAIN OTHER SUBSTANCES FAO Nutrition Meetings Report Series No. 46A WHO/FOOD ADD/70.36 The content of this document is the result of the deliberations of the Joint FAO/WHO Expert Committee on Food Additives which met in Rome, 27 May - 4 June 19691 Food and Agriculture Organization of the United Nations World Health Organization 1 Thirteenth report of the Joint FAO/WHO Expert Committee on Food Additives, FAO Nutrition Meetings Report Series, in press; Wld Hlth Org. techn. Rep. Ser., in press. CARRAGEENAN AND FURCELLARAN This material contains sulfated galactose units. Biological Data Biochemical aspects Rats excrete carrageenan quantitatively in the faeces if administered in the diet at levels of 2-20 per cent. and it therefore has no direct nutritive value (Hawkins & Yaphe, 1965). Oral administration of undegraded carrageenan to guinea-pigs up to 158 mg causes no detectable excretion in the urine. However, if given intraduodenally to guinea-pigs with ligated pylorus, it exerts an antigastric effect. Hence, absorption is still a possibility although its molecular size is very large (Anderson & Soman, 1966). Groups of six rats were fed diets containing 17.4 or 34.8 per cent. carrageenan for three weeks. Weight gain was significantly reduced especially at higher levels. Food efficiency showed interference with utilization of other nutrients in the diet. Only 10-15 per cent. appeared digestible as estimated from faecal examination (Carey, 1958). Using nine groups of three, four or five guinea-pigs it was noted that single intravenous injections of degraded carrageenan leads to a dose-related increase in urinary polysaccharides. Oral or intraduodenal administration of degraded carrageenan gave detectable residues in the urine and had an antigastric activity in guinea-pigs with ligated pylorus. However the amounts absorbed are very small and some additional protective mechanism may be involved (Anderson & Soman, 1966). Carrageenan inhibits pepsin action by binding the substrate (Anderson & Watt, 1959; Piper & Fenton, 1961; and Houck & Bhayana, 1960). Interference with pepsin activity depends on concentration of carrageenan and protein. It occurs only over a narrow range (Márquez & Garcia, 1960; Vaughan et al., 1961; and Vaughan et al., 1962). At a level of five per cent. in the diet of rats carrageenan had no effect on utilization of casein, soybean protein, or of other proteins of variable quality (Friedman & Douglass, 1960). No difference in protein economy of the growing rat was observed with a diet of 0.5-5 per cent. carrageenan and either a high quality protein (casein) or a low quality vegetable protein (USFDA, 1969). Subcutaneous injected carrageenan stimulates the biosynthesis of collagen and the formation of connective tissue (Robertson & Schwartz, 1953; and Jackson, 1956). Three per cent. carrageenan in the diet has been reported to reduce the plasma cholesterol level in chicks by 50 per cent. (Riccardi & Fahrenbach, 1965). Carrageenan acts as an antithrombic in both human and dog blood plasma (Hawkins & Leonhard, 1962). The presence of carrageenan in infant feeds does not affect the availability of any added iron (Gorten et al., 1963; Gorten & Cross, 1964; Owen & Fomon, 1963; Fomon et al., 1961). A seven-month infant feeding study of the nutritional value of Formil an infant formula containing carrageenan (concentration not stated), showed normal results in feeding pattern, growth, bowel function; and serum calcium, phosphorus and cholesterol levels (Marine Colloids, Inc., 1969). Acute toxicity Intravenous injection of undegraded carrageenan is very toxic to rabbits (Anderson & Duncan, 1961). Intravenous injection of 50 mg killed rabbits within 48 h. These animals showed total obstruction of the glomerular capillaries by a fibrinoid-like substance, and extensive tubular neurosis. Rabbits survived 10 mg intravenously, but showed histopathologic changes in the kidney. Similar results were obtained in rats and guinea-pigs. Guinea-pigs survived intravenous injection of 5-10 mg/kg (Morard et al., 1964). Intravenous carrageenan in doses of 1 mg/kg kills guinea-pigs within 30 mins (Anderson & Soman, 1966). The injection of lambda-carrageenan induced collagenous growth in the rabbit cornea (Dass & McCandless). A single injection of 5 ml of a one per cent. carrageenan solution produced sarcomata in female rats and fibrous degeneration of mammillary gland epithelium with hyaline thickening of capillary walls (Cater, 1961). Short-term studies Rat. Groups of six male rats were fed for a 10-week period 0, 5, 10 and 20 per cent. of a refined preparation. The animals grew well except at the highest test level which showed a 50 per cent. mortality (Nilson & Schaller, 1941). In similar feeding experiments using 10 rats there was some growth retardation, decreased food intake and reduced urinary nitrogen excretion at dietary levels over 10 per cent. (Hawkins & Yaphe, 1965). Guinea-pig. Fifty male guinea-pigs were injected daily for 1-41 days with 0.25 mg histamin/100 g body weight in order to induce gastric ulceration. Fifty per cent. carrageenan in the diet did not accentuate the mucosal lesions (Holzmann & Schott, 1963). Man. In a nutritional study of tocopherol requirements an infant formula (Similac) containing carrageenan was fed as the basic diet for six months to 44 healthy premature infants (Goldbloom, 1963). Long-term studies Mouse. Groups of five male and five female mice of two strains were maintained over their life span on diets containing 0, 1 per cent., 5 per cent., 15 per cent. and 25 per cent. carrageenan without apparent ill-effects on growth, survival, gross and histopathology of the gastro-intestinal tract, liver and kidneys (Nilson & Wagner, 1959). Rat. Groups of five male and five female rats of two strains were fed 0, 1 per cent., 5 per cent., 15 per cent. and 25 per cent. carrageenan for their life span. Food consumption increased in proportion to the increased carrageenan content. No effect was noted on mortality. At the 25 per cent. level there was evidence of hepatic cirrhosis but all other levels showed no histopathological abnormalities of the intestinal tract, liver, kidneys. (Nilson & Wagner, 1959). Comments These closely related polysaccharides are very little absorbed when ingested by several animal species. The available short- and long-term studies support the safety of these materials despite the small numbers of animals employed. Carrageenan has a long history of human use without known ill-effect. EVALUATION Level causing no toxicological effect in the rat 10 per cent. (= 100 000 ppm) in the diet equivalent to 5000 mg/kg body weight/day Estimate of acceptable daily intake for man mg/kg body weight Unconditional acceptance 0-501 REFERENCES Anderson, W. & Watt, J. (1959) J. Pharm. (Lond.), 11, 318 Anderson, W. & Duncan, J. G. C. (1965) J. Pharm. (Lond.), 17, 647 Anderson, W. & Soman, P. D. (1966) J. Pharm. (Lond.), 18, 827 Carey P. L. (1958) Thesis submitted to Purdue University Cater, D. B. (1961) Brit. J. Cancer, 15, 607 Dass. B. & McCandless, E. L. (1966) Fed. Proc., 25, 706 Fomon, S. J., Owen, G. M. & Thomas, L. N. (1961) Amer. J. Dis. Child., 108, 601 1 As carrageenan or furcellaran or the sum of both. Friedman, L. & Douglass, C. D. (1960) Unpublished summary report submitted by Marine Colloids Inc. Goldbloom, R. B. (1963) Pediatrics, 32, 36 Gorten, M. K., Hepner, R. & Workman, J. B. (1963) J. Pediat., 63, 1063 Gorten, M. K. & Cross, E. R. (1964) J. Pediat., 64, 509 Hawkins, W. W. & Leonhard, V. G. (1962) J. Lab. clin. Med., 60, 641 Hawkins, W. W. & Yaphe, W. (1965) Canad. J. Biochem., 43, 479 Holzmann, H. & Schott, H. J. (1963) Naturwissenschaften, 50, 502 Houck, J. C. & Bhayana, J. L. (1960) Gastroenterology, 39, 196 Jackson, D. S. (1956) Biochem. J., 62, 250 Marine Colloids Inc. (1969) Unpublished report Márquez, V. M. & Garcia, R. G. (1960) Rev. Fac. Pharmac. (Venezuela), 3, 237 Morard, J. C. et al. (1964) Nature, 202, 401 Nilson, H. W. & Schaller, J. W. (1941) Food Res., 6, 461 Nilson, H. W. & Wagner, J. A. (1959) Food-Res., 24, 235 Owen, G. M. & Fomon, S. J. (1963) Midwest Soc. Pediat. Res., 63, 490 Piper, D. W. & Fenton, B. (1961) Gastroenterology, 40, 638 Riccardi, B. A. & Fahrenbach, M. J. (1965) Fed. Proc., 24, 263 Robertson, W. B. van & Schwartz, B. (1953) J. biol. Chem., 201, 689 United States Food and Drug Administration (1969) Unpublished summary report Vaughan, O. W., Rezabek, H. & Filer, L. J. (1961) Fed. Proc., 20, 863B Vaughan. O. W., Filer, L. J. jr & Churella, H. (1962) Agric. Fd Chem., 10, 517
See Also: Toxicological Abbreviations Carrageenan and Furcellaran (WHO Food Additives Series 5) Carrageenan and furcellaran (WHO Food Additives Series 19)